Skip to main content

Advertisement

Table 1 The scenarios modeled1

From: In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

Scenario (S#) Class # shRNA Efficacy (%) HSC+ (%) Fitness (%)
S0 Untreated     
S1 I & II 6 80n 20 99
S2 I & II 4 80n 20 99
S3 I & II 2 80n 20 99
S4 I & II 6 60n 20 99
S5 I & II 6 80n 1 99
S6 I & II 2 80n 20 50
S7 I & II 2 80n 1 50
S8 I & II 6 80n 20 90
S9 I & II 6 80n 20 50
S10 I & II 2 80n 20 90
S11 II only 6 80n 20 99
  1. 1Twelve scenarios (S#) varied in the number of shRNAs considered (6, 4 and 2 shRNAs), the efficacy of each shRNA (60 or 80%), the proportion of hematopoietic stem cells transduced with the gene therapeutic (HSC+; 20 or 1%), viral fitness (99, 90, or 50%), and the class of treatment (Class I and II). The untreated control (S0) contained only UNTx cells exposed to HIV.